CLASS II Drug recall · Reported 13 Dec 2023 · FDA Enforcement Report

ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg recalled

Staq Pharma is recalling ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/ (2 mg per mL) Injection, distributed nationwide in the US. The recall was initiated on 29 Nov 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: 23109472A, Exp. date 03/10/2024; 23109473A, Exp. date 03/11/2024; 23109474A, Exp. date 03/13/2024; 23109491A, Exp. date 03/16/2024; 23109492A, Exp. date 03/19/2024; 23109501A, Exp. date 03/25/2024; 23109520A, Exp. date 04/10/2024; 23109521A, Exp. date 04/13/2024; 23109522A, Exp. date 04/03/2024.
Quantity recalled2616 bags

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0147-2024
FDA event ID
93505
Recalling firm
Staq Pharma, Denver, CO
Classification
Class II
Status
Completed
Recall initiated
29 Nov 2023
FDA classified
7 Dec 2023
Reported
13 Dec 2023
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Packaging Defects

Timeline

29 Nov 2023Recall initiated by company
7 Dec 2023Classified by FDA+8 days
13 Dec 2023Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma Inc. 14135 E 42nd Ave, Unit 50, Denver, Colorado 80239, NDC 73177-0109-26,

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Why was it recalled?

STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

Which lots are affected?

Lot#: 23109472A, Exp. date 03/10/2024; 23109473A, Exp. date 03/11/2024; 23109474A, Exp. date 03/13/2024; 23109491A, Exp. date 03/16/2024; 23109492A, Exp. date 03/19/2024; 23109501A, Exp. date 03/25/2024; 23109520A, Exp. date 04/10/2024; 23109521A, Exp. date 04/13/2024; 23109522A, Exp. date 04/03/2024.

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Staq Pharma

All 6

Other Ropivacaine Pf recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIRopivacaine HCL (PF) 0.2% (2mg/mL) Cassette recalledBanner Pharmacy ServicesSterilityNationwide